AN2 Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2021 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AN2 Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2021 to Q4 2024.
  • AN2 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $1.78M, a 22.5% decline year-over-year.
  • AN2 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $8.34M, a 0.88% decline year-over-year.
  • AN2 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8.34M, a 0.88% decline from 2023.
  • AN2 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8.41M, a 91.6% increase from 2022.
  • AN2 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.39M, a 351% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $8.34M $1.78M -$518K -22.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-25
Q3 2024 $8.86M $1.9M -$267K -12.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $9.12M $2.27M +$328K +16.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $8.8M $2.39M +$383K +19.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $8.41M $2.3M +$826K +56.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-25
Q3 2023 $7.59M $2.17M +$941K +76.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $6.65M $1.94M +$701K +56.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $5.94M $2M +$1.55M +346% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $4.39M $1.47M +$1.04M +239% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $3.35M $1.23M +$875K +248% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.48M $1.24M +$1.06M +594% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $1.42M $449K +$441K +5513% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $974K $434K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $353K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $179K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $8K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.